Abdominal Fat, Diabetes Mellitus, Type 2, Metabolism Disorder, Glucose, Metabolism Disorder, Lipid, Metformin, Non-Alcoholic Fatty Liver Disease, Obesity, Abdominal
Conditions
Keywords
Metformin, Glucagon-Like Peptide-1 Receptor, Obesity, Abdominal, Diabetes Mellitus, Type 2, Non-Alcoholic Fatty Liver Disease, Metabolism Disorder, Glucose
Brief summary
The purpose of this study is to analyze the effects of GLP-1RA on blood glucose, body weight, glucose and lipid metabolism and fat distribution in overweight/obese patients with type 2 diabetes mellitus.
Detailed description
Specific research contents: To study the characteristics of glucose and lipid metabolism and fat distribution in overweight/obesity patients with type 2 diabetes mellitus; liraglutide/ semaglutide/ metformin will be applied to patients for one year, and the changes of lipid metabolism and fat distribution in overweight/obese patients with type 2 diabetes and the differences among the three groups will be analyzed before and after treatment. The metabolomic changes of overweight/obese patients with type 2 diabetes before and after medication and the differences among the three groups will be analyzed. Explore the correlation between visceral fat content, glucose and lipid metabolism, inflammatory factors and other biochemical indicators and metabolomics.
Interventions
DRUGLiraglutide
Liraglutide is injected once a day.
DRUGSemaglutide
Semaglutide is injected once a week.
DRUGMetformin
Metformin is taken orally daily.
Sponsors
RenJi Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Aged 18-65 years old * BMI≥24kg/㎡, or waist circumference: \> 85cm (for male) or \> 80cm (for female) * Has been diagnosed with type 2 diabetes mellitus * Good blood glucose control in recent three months: random blood sugar \< 14mmol/L and HbA1c 6-9% * Not received any drugs affecting glucose and lipid metabolism or weight loss surgery in the past one month
Exclusion criteria
* Abnormal weight gain caused by other endocrine diseases * Severe metabolic diseases, such as diabetic ketoacidosis, hypertonic hyperglycemia * Type 1 diabetes or other special types of diabetes * Used drugs affecting glycolipid metabolism in the past three months * Severe bleeding tendency that unable to complete venous blood collection * Patients with MRI contraindications * Severe renal insufficiency or severe liver insufficiency * Patients with advanced malignant tumors * Serious cardiovascular and cerebrovascular diseases * Rheumatic and immune diseases * Pregnant and lactating women
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Blood glucose | The twelfth week of treatment | Glucose metabolism index |
| Blood insulin | The twelfth week of treatment | Glucose metabolism index |
| Total cholesterol | The twelfth week of treatment | Lipid metabolism index |
| Triglyceride | The twelfth week of treatment | Lipid metabolism index |
| Lipoprotein | The twelfth week of treatment | Lipid metabolism index |
| Weight | The twelfth week of treatment | Measure fasting weight |
| Abdominal fat distribution | The twelfth week of treatment | Use Magnetic resonance imaging-proton density fat fraction to measure fat accumulation in the liver, pancreas and abdomen. |
Countries
China
Outcome results
None listed